论文部分内容阅读
目的:探讨乳腺癌不同分子分型的临床病理特征及预后情况。方法:选取2012年1月-2014年9月于我院就诊并行手术治疗的乳腺癌患者共405例,所有患者均经免疫组化中雌激素(ER)、孕激素(PR)、人表皮生长因子受体-2(HER-2)、CK5/6及Ki-67检测分为Luminal A型、Luminal B型、HER-2过表达型及基底样型(Basal-like)、正常乳腺样型(Normol-breast-like),对比不同分子分型临床病理特征及预后情况。结果:Luminal A型60例(14.8%),Luminal B型245例(60.5%),HER-2过表达型61例(15.1%),Basal-like 28例(6.9%),Normol-breastlike 11例(2.7%)。不同分子分型在年龄、肿块大小、淋巴结转移数目、临床分期、组织学分级等比较,差异均具统计学意义(P<0.05);Basal-like复发及远处转移率较高,预后最差,其5年生存率低;HER-2过表达型、Normol-breastlike预后较差;Luminal B型预后较好;Luminal A型预后最好。结论:乳腺癌不同分子分型临床病理及预后情况均具有明显差异,与乳腺癌组织学分型相比更能对临床精准治疗及预后判断提供指导性意义。
Objective: To investigate the clinicopathological features and prognosis of different molecular types of breast cancer. Methods: A total of 405 patients with breast cancer who underwent surgical treatment in our hospital from January 2012 to September 2014 were enrolled in this study. All patients underwent immunohistochemistry for estrogen (ER), progesterone (PR), human epidermal growth The expression of HER-2, CK5 / 6 and Ki-67 were detected by Luminal A, Luminal B, HER-2 overexpression and basal-like, Normol-breast-like), comparing different molecular classification of clinicopathological features and prognosis. Results: There were 60 cases (14.8%) of Luminal A type, 245 cases (60.5%) of Luminal B type, 61 (15.1%) cases of HER-2 overexpression, 28 cases of Basal-like (2.7%). The differences of different molecular types were statistically significant (P <0.05) in age, tumor size, number of lymph node metastasis, clinical stage and histological grading. The rate of Basal-like recurrence and distant metastasis was the highest, with the worst prognosis , The 5-year survival rate is low; HER-2 overexpression, Normol-breastlike prognosis is poor; Luminal B type prognosis is better; Luminal A type prognosis is the best. Conclusion: There are significant differences in the clinicopathological features and prognosis of different molecular types of breast cancer, which may provide guidance for clinical precise treatment and prognosis compared with histological classification of breast cancer.